Literature DB >> 29416129

B cells in the pathogenesis of primary Sjögren syndrome.

Gaëtane Nocturne1, Xavier Mariette1.   

Abstract

Primary Sjögren syndrome (pSS) is a prototypical autoimmune disease. The involvement of B cells in the pathogenesis of pSS has long been suspected on the basis of clinical observations that include the presence of serum autoantibodies, hypergammaglobulinaemia, increased levels of free light chains and increased risk of B cell lymphoma. Moreover, the composition of the B cell subset is altered in pSS. In this Review, we discuss the mechanisms that support the increased activation of B cells in pSS, including genetic and epigenetic factors and environmental triggers that promote B cell activation via the innate immune system. B cell activating factor (BAFF, also known as TNF ligand superfamily member 13B) is at the crossroads of this process. An important role also exists for the target tissue (exocrine glands, namely the salivary and lachrymal glands), which promotes local B cell activation. This continuous stimulation of B cells is the main driver of lymphomatous escape. Identification of the multiple steps that support B cell activation has led to the development of promising targeted therapies that will hopefully lead to the development of an efficient therapeutic strategy for pSS.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29416129     DOI: 10.1038/nrrheum.2018.1

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  150 in total

1.  BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome.

Authors:  Frédérique d'Arbonneau; Jacques-Olivier Pers; Valérie Devauchelle; Yvon Pennec; Alain Saraux; Pierre Youinou
Journal:  Arthritis Rheum       Date:  2006-01

2.  BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.

Authors:  Luca Quartuccio; Sara Salvin; Martina Fabris; Marta Maset; Elena Pontarini; Miriam Isola; Salvatore De Vita
Journal:  Rheumatology (Oxford)       Date:  2012-08-09       Impact factor: 7.580

3.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Authors:  Frédéric Lavie; Corinne Miceli-Richard; Marc Ittah; Jérémie Sellam; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-10-13       Impact factor: 19.103

4.  The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome.

Authors:  Anna P Risselada; Aike A Kruize; Roel Goldschmeding; Floris P J G Lafeber; Johannes W J Bijlsma; Joel A G van Roon
Journal:  Ann Rheum Dis       Date:  2014-02-13       Impact factor: 19.103

5.  Epigenetic dysregulation in salivary glands from patients with primary Sjögren's syndrome may be ascribed to infiltrating B cells.

Authors:  Yosra Thabet; Christelle Le Dantec; Ibtissem Ghedira; Valérie Devauchelle; Divi Cornec; Jacques-Olivier Pers; Yves Renaudineau
Journal:  J Autoimmun       Date:  2013-03-07       Impact factor: 7.094

6.  Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome.

Authors:  P Tengnér; A K Halse; H J Haga; R Jonsson; M Wahren-Herlenius
Journal:  Arthritis Rheum       Date:  1998-12

7.  Novel autoantibodies in Sjogren's syndrome.

Authors:  Long Shen; Lakshmanan Suresh; Matthew Lindemann; Jingxiu Xuan; Przemek Kowal; Kishore Malyavantham; Julian L Ambrus
Journal:  Clin Immunol       Date:  2012-10-12       Impact factor: 3.969

8.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

9.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.

Authors:  Richard J Bende; Wilhelmina M Aarts; Robert G Riedl; Daphne de Jong; Steven T Pals; Carel J M van Noesel
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

10.  Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma.

Authors:  Gaetane Nocturne; Jessica Tarn; Saida Boudaoud; James Locke; Corinne Miceli-Richard; Eric Hachulla; Jean-Jacques Dubost; Simon Bowman; Jacques-Eric Gottenberg; Lindsey A Criswell; Christopher J Lessard; Kathy L Sivils; Raphael Carapito; Siamak Bahram; Raphaèle Seror; Wan-Fai Ng; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2015-09-02       Impact factor: 19.103

View more
  77 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

2.  CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.

Authors:  Yuki Imura; Makoto Ando; Taisuke Kondo; Minako Ito; Akihiko Yoshimura
Journal:  JCI Insight       Date:  2020-07-23

3.  Conditions associated with polyclonal hypergammaglobulinemia in the IgG4-related disease era: a retrospective study from a hematology tertiary care center.

Authors:  Eric J Zhao; Mollie N Carruthers; Charles H Li; Andre Mattman; Luke Y C Chen
Journal:  Haematologica       Date:  2019-06-27       Impact factor: 9.941

4.  Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma.

Authors:  Gaetane Nocturne; Elena Pontarini; Michele Bombardieri; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-03-05       Impact factor: 7.580

5.  Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Authors:  Hajir Ibraheim; Esperanza Perucha; Nick Powell
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 6.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

7.  Epstein - Barr virus Infection in a Patient with Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: A Case Report and Review of Literature.

Authors:  Justin B Levinson; Milena Rodriguez Alvarez; Kristaq Koci; Aleksander Feoktistov; Isabel M McFarlane
Journal:  Clin Case Rep Rev       Date:  2018-05-31

8.  TLR7 Signaling Drives the Development of Sjögren's Syndrome.

Authors:  Yawen Wang; Annie Roussel-Queval; Lionel Chasson; Noël Hanna Kazazian; Laetitia Marcadet; Andrianos Nezos; Michael H Sieweke; Clio Mavragani; Lena Alexopoulou
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

Review 9.  Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD).

Authors:  J N Pouw; E F A Leijten; J M van Laar; M Boes
Journal:  Clin Exp Immunol       Date:  2020-11-15       Impact factor: 4.330

Review 10.  B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells.

Authors:  Carlo G Bonasia; Wayel H Abdulahad; Abraham Rutgers; Peter Heeringa; Nicolaas A Bos
Journal:  Cells       Date:  2021-05-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.